8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Apr 9, 2026·SEC
Material company update
Mar 26, 2026·SEC
NovoCure Limited(NVCR)Earnings, Financials & Key Ratios
NVCR•NASDAQ
Price updated Jun 19, 2026
AboutNovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.Show more
- Revenue$655M+8.3%
- EBITDA-$137M+14.2%
- Net Income-$136M+19.2%
- EPS (Diluted)-1.22+21.8%
- Gross Margin74.54%-3.6%
- EBITDA Margin-20.84%+20.8%
- Operating Margin-23.47%+16.7%
- Net Margin-20.79%+25.4%
- ROE-38.89%+16.7%
NVCR Key Insights
NovoCure Limited (NVCR) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when NVCR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NVCR Price & Volume
NovoCure Limited (NVCR) stock price & volume — 10-year historical chart
Loading chart...
NVCR Growth Metrics
NovoCure Limited (NVCR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years34.8%
5 Years5.8%
3 Years6.81%
TTM8.48%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-5.4%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-1.32%
Return on Capital
10 Years-15.96%
5 Years-17.81%
3 Years-25.22%
Last Year-28.87%
NVCR Recent Earnings
NovoCure Limited (NVCR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
Apr 30, 2026Metric
Actual
Est
EPS
$0.62-21.0%
$0.51
Rev
$174M+3.7%
$168M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.22+46.3%
$0.41
Rev
$174M-0.0%
$174M
Q4 2025
Oct 30, 2025Metric
Actual
Est
EPS
$0.33+21.4%
$0.42
Rev
$167M-4.1%
$174M
Q3 2025
Jul 24, 2025Metric
Actual
Est
EPS
$0.36+7.7%
$0.39
Rev
$159M-0.0%
$159M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $0.62vs $0.51-21.0% | $174Mvs $168M+3.7% |
| Q1 2026 | Feb 26, 2026 | $0.22vs $0.41+46.3% | $174Mvs $174M-0.0% |
| Q4 2025 | Oct 30, 2025 | $0.33vs $0.42+21.4% | $167Mvs $174M-4.1% |
| Q3 2025 | Jul 24, 2025 | $0.36vs $0.39+7.7% | $159Mvs $159M-0.0% |
Based on last 12 quarters of dataView full earnings history →
NVCR Peer Comparison
NovoCure Limited (NVCR) competitors in Patient monitoring and respiratory care — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 | |
 SUPN | 2.56B | 44.38 | -65.26 | 8.63% | -3.74% | -2.73% | 0.04 | |
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 IDXX | 44.64B | 562.09 | 42.97 | 10.42% | 24.63% | 70.87% | 0.67 | |
 HOLX | 16.97B | 76.01 | 30.53 | 1.74% | 13.18% | 11.01% | 0.52 | |
 MASI | 9.42B | 179.95 | -64.27 | -27.1% | 4.9% | 9.08% | 0.78 | |
 INMD | 849.01M | 13.40 | 9.37 | -6.16% | 23.27% | 13.28% | 0.02 |
Compare NVCR vs Peers
NovoCure Limited (NVCR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NVCR Income Statement
NovoCure Limited (NVCR) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 177.03M | 248.07M | 351.32M | 494.37M | 535.03M | 537.84M | 509.34M | 605.22M | 655.35M | 674.41M |
Revenue Growth % | 113.57% | 40.13% | 41.62% | 40.72% | 8.23% | 0.53% | -5.3% | 18.82% | 8.28% | 8.48% |
Cost of Goods Sold | 55.61M | 80.05M | 88.61M | 106.5M | 114.88M | 114.87M | 128.28M | 137.18M | 166.88M | 167.29M |
COGS % of Revenue | 31.41% | 32.27% | 25.22% | 21.54% | 21.47% | 21.36% | 25.19% | 22.67% | 25.46% | - |
Gross Profit | 121.42M▲ 0% | 168.02M▲ 38.4% | 262.71M▲ 56.4% | 387.87M▲ 47.6% | 420.15M▲ 8.3% | 422.97M▲ 0.7% | 381.06M▼ 9.9% | 468.04M▲ 22.8% | 488.47M▲ 4.4% | 507.13M▲ 0% |
Gross Margin % | 68.59% | 67.73% | 74.78% | 78.46% | 78.53% | 78.64% | 74.81% | 77.33% | 74.54% | 75.2% |
Gross Profit Growth % | 231.69% | 38.38% | 56.36% | 47.64% | 8.32% | 0.67% | -9.91% | 22.83% | 4.37% | - |
Operating Expenses | 160.75M | 201.69M | 263.63M | 357.46M | 464.49M | 512.5M | 614.67M | 638.53M | 642.27M | 690.48M |
OpEx % of Revenue | 90.8% | 81.31% | 75.04% | 72.31% | 86.81% | 95.29% | 120.68% | 105.5% | 98% | - |
Selling, General & Admin | 122.64M | 151.12M | 184.62M | 225.45M | 263.18M | 306.41M | 390.87M | 428.89M | 417.73M | 461.38M |
SG&A % of Revenue | 69.28% | 60.92% | 52.55% | 45.6% | 49.19% | 56.97% | 76.74% | 70.87% | 63.74% | - |
Research & Development | 38.1M | 50.57M | 79M | 132.01M | 201.3M | 206.09M | 223.06M | 209.65M | 224.54M | 229.1M |
R&D % of Revenue | 21.52% | 20.39% | 22.49% | 26.7% | 37.62% | 38.32% | 43.79% | 34.64% | 34.26% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -39.33M▲ 0% | -33.67M▲ 14.4% | -914K▲ 97.3% | 30.4M▲ 3426.1% | -44.33M▼ 245.8% | -89.52M▼ 101.9% | -232.87M▼ 160.1% | -170.5M▲ 26.8% | -153.8M▲ 9.8% | -183.35M▲ 0% |
Operating Margin % | -22.22% | -13.57% | -0.26% | 6.15% | -8.29% | -16.64% | -45.72% | -28.17% | -23.47% | -27.19% |
Operating Income Growth % | 65.9% | 14.38% | 97.29% | 3426.15% | -245.83% | -101.93% | -160.12% | 26.78% | 9.79% | - |
EBITDA | -31.65M | -24.67M | 7.48M | 39.55M | -34.08M | -78.9M | -221.9M | -159.26M | -136.6M | -165.36M |
EBITDA Margin % | -17.88% | -9.94% | 2.13% | 8% | -6.37% | -14.67% | -43.57% | -26.31% | -20.84% | -24.52% |
EBITDA Growth % | 71.14% | 22.07% | 130.32% | 428.83% | -186.17% | -131.5% | -181.25% | 28.23% | 14.23% | -6.6% |
D&A (Non-Cash Add-back) | 7.68M | 9.01M | 8.39M | 9.15M | 10.25M | 10.62M | 10.97M | 11.23M | 17.2M | 18M |
EBIT | -36.8M | -32.45M | 5.05M | 35.68M | -48.63M | -78.51M | -188.42M | -120.82M | -136.25M | -177.92M |
Net Interest Income | -9.72M | -12.27M | -7.91M | -12.3M | -7.74M | 7.68M | 41.13M | 39.33M | 18.11M | 8.7M |
Interest Income | 1.98M | 4.64M | 6.73M | 5.75M | 1.1M | 15.79M | 46.04M | 51M | 18.11M | 10.54M |
Interest Expense | 11.69M | 16.91M | 14.64M | 18.05M | 8.84M | 8.11M | 4.91M | 11.66M | 0 | 1.84M |
Other Income/Expense | -9.17M | -12.27M | -7.91M | -12.3M | -7.74M | 7.68M | 41.13M | 39.33M | 17.55M | 8.14M |
Pretax Income | -48.5M▲ 0% | -45.94M▲ 5.3% | -8.82M▲ 80.8% | 18.1M▲ 305.1% | -52.08M▼ 387.7% | -81.85M▼ 57.2% | -191.74M▼ 134.3% | -131.16M▲ 31.6% | -136.25M▼ 3.9% | -175.21M▲ 0% |
Pretax Margin % | -27.4% | -18.52% | -2.51% | 3.66% | -9.73% | -15.22% | -37.64% | -21.67% | -20.79% | -25.98% |
Income Tax | 13.16M | 17.62M | -1.59M | -1.71M | 6.28M | 10.69M | 15.3M | 37.47M | -23K | -2.17M |
Effective Tax Rate % | -27.15% | -38.35% | 18.06% | -9.42% | -12.05% | -13.06% | -7.98% | -28.56% | 0.02% | 1.24% |
Net Income | -61.66M▲ 0% | -63.56M▼ 3.1% | -7.23M▲ 88.6% | 19.81M▲ 374.0% | -58.35M▼ 394.6% | -92.53M▼ 58.6% | -207.04M▼ 123.7% | -168.63M▲ 18.6% | -136.23M▲ 19.2% | -173.05M▲ 0% |
Net Margin % | -34.83% | -25.62% | -2.06% | 4.01% | -10.91% | -17.2% | -40.65% | -27.86% | -20.79% | -25.66% |
Net Income Growth % | 53.23% | -3.08% | 88.62% | 373.97% | -394.58% | -58.58% | -123.75% | 18.55% | 19.21% | -5.4% |
Net Income (Continuing) | -61.66M | -63.56M | -7.23M | 19.81M | -58.35M | -92.53M | -207.04M | -168.63M | -136.23M | -173.05M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.70▲ 0% | -0.69▲ 1.4% | -0.07▲ 89.2% | 0.18▲ 341.9% | -0.56▼ 411.1% | -0.88▼ 57.1% | -1.95▼ 121.6% | -1.56▲ 20.0% | -1.22▲ 21.8% | -1.52▲ 0% |
EPS Growth % | 54.55% | 1.43% | 89.22% | 341.94% | -411.11% | -57.14% | -121.59% | 20% | 21.79% | -1.32% |
EPS (Basic) | -0.70 | -0.69 | -0.07 | 0.20 | -0.56 | -0.88 | -1.95 | -1.56 | -1.22 | - |
Diluted Shares Outstanding | 88.55M | 91.83M | 97.24M | 108.88M | 103.43M | 104.66M | 106.39M | 107.83M | 111.47M | 114.15M |
Basic Shares Outstanding | 88.55M | 91.83M | 97.24M | 100.93M | 103.43M | 104.66M | 106.39M | 107.83M | 111.47M | 114.15M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
NVCR Balance Sheet
NovoCure Limited (NVCR) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 245.13M | 321.37M | 439.95M | 999.44M | 1.07B | 1.11B | 1.03B | 1.11B | 646.73M | 631.66M |
Cash & Short-Term Investments | 183.31M | 245.88M | 328.19M | 854.08M | 938.51M | 969.42M | 910.62M | 959.87M | 457.52M | 441.8M |
Cash Only | 78.59M | 140.62M | 179.42M | 246.17M | 209.61M | 115.33M | 240.82M | 163.77M | 103.39M | 97.32M |
Short-Term Investments | 104.72M | 105.26M | 148.77M | 607.9M | 728.9M | 854.1M | 669.79M | 796.11M | 354.13M | 344.48M |
Accounts Receivable | 29.57M | 36.52M | 63.96M | 100.47M | 97.41M | 86.26M | 77.11M | 102.07M | 115.35M | 93.27M |
Days Sales Outstanding | 60.96 | 53.74 | 66.45 | 74.18 | 66.45 | 58.54 | 55.26 | 61.56 | 64.24 | 57.22 |
Inventory | 22.02M | 22.55M | 23.7M | 27.42M | 24.43M | 29.38M | 38.15M | 35.09M | 0 | 43.46M |
Days Inventory Outstanding | 144.57 | 102.85 | 97.63 | 93.98 | 77.61 | 93.34 | 108.56 | 93.35 | - | 45.64 |
Other Current Assets | 2.13M | 2.13M | 21.85M | 13.51M | 8.47M | 20.05M | 1.74M | 2.33M | 73.87M | 53.13M |
Total Non-Current Assets | 20.16M | 18.42M | 39.5M | 52.54M | 65.97M | 80.12M | 111.72M | 134.21M | 157.59M | 156.26M |
Property, Plant & Equipment | 18.07M | 15.37M | 34.6M | 41.63M | 53.88M | 68.96M | 97.7M | 119.59M | 0 | 145.06M |
Fixed Asset Turnover | 9.80x | 16.14x | 10.15x | 11.87x | 9.93x | 7.80x | 5.21x | 5.06x | - | 9.24x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 2.1M | 3.06M | 4.9M | 10.91M | 12.09M | 11.16M | 14.02M | 14.62M | 157.59M | 11.2M |
Total Assets | 265.3M▲ 0% | 339.79M▲ 28.1% | 479.45M▲ 41.1% | 1.05B▲ 119.4% | 1.14B▲ 8.3% | 1.19B▲ 4.6% | 1.15B▼ 3.8% | 1.24B▲ 8.3% | 804.33M▼ 35.2% | 787.93M▲ 0% |
Asset Turnover | 0.67x | 0.73x | 0.73x | 0.47x | 0.47x | 0.45x | 0.44x | 0.49x | 0.81x | 0.64x |
Asset Growth % | -5.95% | 28.08% | 41.1% | 119.42% | 8.32% | 4.58% | -3.82% | 8.26% | -35.18% | -57.91% |
Total Current Liabilities | 50.2M | 64.56M | 86.31M | 113.61M | 142.6M | 158.78M | 179.12M | 756.38M | 223.23M | 217.58M |
Accounts Payable | 17.21M | 26.71M | 36.92M | 53.65M | 72.6M | 85.2M | 94.39M | 105.09M | 122.23M | 127.24M |
Days Payables Outstanding | 112.93 | 121.78 | 152.11 | 183.86 | 230.67 | 270.72 | 268.57 | 279.6 | 267.35 | 257.5 |
Short-Term Debt | 0 | 0 | 4.63M | 6.48M | 6.68M | 0 | 0 | 558.16M | 11.66M | 0 |
Deferred Revenue (Current) | 4.96M | 8.84M | 11.77M | 17.77M | 17.76M | 18.03M | 16.22M | 14.22M | 15.95M | 0 |
Other Current Liabilities | 5.64M | 12.26M | 64K | 61K | 169K | 0 | 0 | 0 | 9.03M | 90.34M |
Current Ratio | 4.88x | 4.98x | 5.10x | 8.80x | 7.53x | 7.00x | 5.78x | 1.46x | 2.90x | 2.90x |
Quick Ratio | 4.44x | 4.63x | 4.82x | 8.56x | 7.36x | 6.82x | 5.56x | 1.42x | 2.90x | 2.70x |
Cash Conversion Cycle | 92.59 | 34.8 | 11.97 | -15.7 | -86.61 | -118.84 | -104.76 | -124.69 | - | -154.64 |
Total Non-Current Liabilities | 101.53M | 162.97M | 175.35M | 461.85M | 586.4M | 591.7M | 604.52M | 124.23M | 240.63M | 239.63M |
Long-Term Debt | 97.34M | 149.27M | 149.42M | 429.9M | 562.22M | 565.51M | 568.82M | 97.3M | 236.69M | 195.46M |
Capital Lease Obligations | 0 | 0 | 14.14M | 14.29M | 13M | 18.76M | 27.42M | 19.97M | 41.65M | 166.66M |
Deferred Tax Liabilities | 0 | 124K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 4.19M | 3.65M | 3.98M | 5.51M | 4.71M | 4.55M | 8.28M | 6.96M | -37.71M | 4.69M |
Total Liabilities | 151.73M | 227.53M | 261.66M | 575.46M | 729M | 750.48M | 783.63M | 880.61M | 463.86M | 457.21M |
Total Debt | 97.34M | 149.27M | 168.2M | 450.68M | 581.9M | 584.27M | 596.24M | 683.35M | 290M | 234.94M |
Net Debt | 18.75M | 8.65M | -11.22M | 204.51M | 372.29M | 468.94M | 355.42M | 519.59M | 186.61M | 137.62M |
Debt / Equity | 0.86x | 1.33x | 0.77x | 0.95x | 1.42x | 1.32x | 1.64x | 1.90x | 0.85x | 0.71x |
Debt / EBITDA | - | - | 22.49x | 11.39x | - | - | - | - | - | -1.42x |
Net Debt / EBITDA | - | - | -1.50x | 5.17x | - | - | - | - | - | -0.83x |
Interest Coverage | -3.15x | -1.92x | 0.34x | 1.98x | -5.50x | -9.68x | -38.41x | -10.36x | - | -96.80x |
Total Equity | 113.56M▲ 0% | 112.26M▼ 1.1% | 217.79M▲ 94.0% | 476.53M▲ 118.8% | 410.49M▼ 13.9% | 441.17M▲ 7.5% | 362.5M▼ 17.8% | 360.18M▼ 0.6% | 340.47M▼ 5.5% | 330.72M▲ 0% |
Equity Growth % | -20.22% | -1.15% | 94.01% | 118.8% | -13.86% | 7.47% | -17.83% | -0.64% | -5.47% | -22.9% |
Book Value per Share | 1.28 | 1.22 | 2.24 | 4.38 | 3.97 | 4.22 | 3.41 | 3.34 | 3.05 | 2.90 |
Total Shareholders' Equity | 113.56M | 112.26M | 217.79M | 476.53M | 410.49M | 441.17M | 362.5M | 360.18M | 340.47M | 330.72M |
Common Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | -582.26M | -643.65M | -650.88M | -631.08M | -685.93M | -778.46M | -985.5M | -1.15B | -1.29B | -1.36B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -1.34M | -1.4M | -2.77M | -3.83M | -3.17M | -2.43M | -5.47M | -5.5M | -3.44M | -4.89M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NVCR Cash Flow Statement
NovoCure Limited (NVCR) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -33.13M | -1.86M | 26.62M | 99.15M | 82.76M | 30.79M | -73.34M | -26.37M | -49.03M | -26.88M |
Operating CF Margin % | -18.72% | -0.75% | 7.58% | 20.06% | 15.47% | 5.72% | -14.4% | -4.36% | -7.48% | - |
Operating CF Growth % | 69.2% | 94.37% | 1527.35% | 272.46% | -16.53% | -62.8% | -338.2% | 64.04% | -85.94% | -1087.83% |
Net Income | -61.66M | -63.56M | -7.23M | 19.81M | -58.35M | -92.53M | -207.04M | -168.63M | -136.23M | -173.05M |
Depreciation & Amortization | 7.68M | 9.01M | 8.46M | 9.15M | 10.25M | 10.62M | 10.97M | -14.41M | 14.65M | 6.43M |
Stock-Based Compensation | 27.12M | 39.85M | 52.42M | 75.72M | 94.9M | 106.95M | 115.61M | 160.03M | 0 | 118.47M |
Deferred Taxes | 241K | 407K | -519K | -270K | 3.88M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 252K | 1.02M | -2.17M | 3.26M | 3.01M | -6.05M | -22.43M | 932K | 87.67M | 12.52M |
Working Capital Changes | -6.76M | 11.41M | -24.33M | -8.52M | 29.07M | 11.8M | 29.56M | -4.3M | -15.13M | 8.74M |
Change in Receivables | -23.23M | -4.15M | -36.5M | -30.35M | 5.27M | 2.55M | 29.41M | -26.36M | -38.94M | -29.5M |
Change in Inventory | 3.52M | -529K | -1.16M | -2.94M | 2.48M | -4.34M | -8.92M | 2.57M | -5.67M | -4.5M |
Change in Payables | -1.15M | 9.5M | 16.88M | 25.47M | 27.78M | 14.26M | 14.87M | 19.11M | 18.96M | 30.26M |
Cash from Investing | 6.77M | -5.49M | -51.67M | -472.85M | -144.83M | -139.96M | 184.15M | -140.24M | 437.28M | 451.5M |
Capital Expenditures | -7.37M | -6.71M | -10.48M | -14.97M | -24.17M | -21.36M | -27.09M | -42.85M | -26.65M | -21.19M |
CapEx % of Revenue | 4.16% | 2.71% | 2.98% | 3.03% | 4.52% | 3.97% | 5.32% | 7.08% | 4.07% | 3.14% |
Acquisitions | 0 | 3.79M | 41.18M | 457.88M | 120.66M | 118.6M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -1.86M | -3.79M | -41.18M | -457.88M | -120.66M | -118.6M | 0 | 0 | 0 | 0 |
Cash from Financing | 5.17M | 69.37M | 61.68M | 440.21M | 25.7M | 15.49M | 15.79M | 90.31M | -451.34M | -456.76M |
Debt Issued (Net) | -57K | 49.07M | -31K | 408.41M | -26K | -28K | -10K | 84.01M | -460.97M | -460.97M |
Equity Issued (Net) | 1.54M | 1.83M | 2.47M | 3.37M | 4.55M | 5.22M | 4.42M | 4.15M | 9.77M | 4.27M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 3.69M | 18.47M | 59.24M | 28.43M | 21.18M | 10.29M | 11.38M | 2.16M | -146K | -61K |
Net Change in Cash | -21.19M▲ 0% | 62.04M▲ 392.8% | 36.66M▼ 40.9% | 66.76M▲ 82.1% | -36.56M▼ 154.8% | -93.78M▼ 156.5% | 126.73M▲ 235.1% | -76.47M▼ 160.3% | -62.7M▲ 18.0% | -32.11M▲ 0% |
Free Cash Flow | -40.5M▲ 0% | -8.58M▲ 78.8% | 16.14M▲ 288.1% | 84.18M▲ 421.7% | 58.59M▼ 30.4% | 9.43M▼ 83.9% | -100.43M▼ 1165.0% | -69.22M▲ 31.1% | -75.68M▼ 9.3% | -48.07M▲ 0% |
FCF Margin % | -22.88% | -3.46% | 4.59% | 17.03% | 10.95% | 1.75% | -19.72% | -11.44% | -11.55% | -7.13% |
FCF Growth % | 67.67% | 78.82% | 288.14% | 421.72% | -30.4% | -83.9% | -1164.99% | 31.07% | -9.32% | 33.36% |
FCF per Share | -0.46 | -0.09 | 0.17 | 0.77 | 0.57 | 0.09 | -0.94 | -0.64 | -0.68 | -0.42 |
FCF Conversion (FCF/Net Income) | 0.54x | 0.03x | -3.68x | 5.01x | -1.42x | -0.33x | 0.35x | 0.16x | 0.36x | 0.28x |
Interest Paid | 10.16M | 13.33M | 13.7M | 0 | 101K | 41K | 6K | 7.71M | 0 | 2.67M |
Taxes Paid | 10.29M | 20.35M | 11.24M | 0 | 3.11M | 5.48M | 13.66M | 23.46M | 0 | 13.84M |
NVCR Key Ratios
NovoCure Limited (NVCR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -48.19% | -56.29% | -4.38% | 5.71% | -13.16% | -21.73% | -51.52% | -46.67% | -38.89% | -50.82% |
Return on Invested Capital (ROIC) | -21.76% | -19.95% | -0.42% | 5.14% | -4.54% | -7.93% | -21.46% | -16.01% | -16.4% | -20.45% |
Gross Margin | 68.59% | 67.73% | 74.78% | 78.46% | 78.53% | 78.64% | 74.81% | 77.33% | 74.54% | 75.2% |
Net Margin | -34.83% | -25.62% | -2.06% | 4.01% | -10.91% | -17.2% | -40.65% | -27.86% | -20.79% | -25.66% |
Debt / Equity | 0.86x | 1.33x | 0.77x | 0.95x | 1.42x | 1.32x | 1.64x | 1.90x | 0.85x | 0.71x |
Interest Coverage | -3.15x | -1.92x | 0.34x | 1.98x | -5.50x | -9.68x | -38.41x | -10.36x | - | -96.80x |
FCF Conversion | 0.54x | 0.03x | -3.68x | 5.01x | -1.42x | -0.33x | 0.35x | 0.16x | 0.36x | 0.28x |
Revenue Growth | 113.57% | 40.13% | 41.62% | 40.72% | 8.23% | 0.53% | -5.3% | 18.82% | 8.28% | 8.48% |
Related:NVCR Dividend History·NVCR Revenue History·NVCR Price History·NVCR P/E History·NVCR Financial Ratios·NVCR Institutional Holders
NVCR SEC Filings & Documents
NovoCure Limited (NVCR) SEC filings — annual & quarterly reports (10-K, 10-Q)
NVCR Frequently Asked Questions
NovoCure Limited (NVCR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
NovoCure Limited (NVCR) reported $674.4M in revenue for fiscal year 2025. This represents a 6410% increase from $10.4M in 2013.
NovoCure Limited (NVCR) grew revenue by 8.3% over the past year. This is steady growth.
NovoCure Limited (NVCR) reported a net loss of $173.0M for fiscal year 2025.
Dividend & Returns
NovoCure Limited (NVCR) has a return on equity (ROE) of -38.9%. Negative ROE indicates the company is unprofitable.
NovoCure Limited (NVCR) had negative free cash flow of $48.1M in fiscal year 2025, likely due to heavy capital investments.